All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
An oral session on lymphoma took place at the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting on 19 March 2018. Abstract OS1-1 was presented by Charalampia Kyriakou, hematology consultant from the Royal Free London NHS foundation, who discussed the outcomes of a consensus on the role of autologous stem cell transplantation (ASCT) and allogeneic stem cell transplantation (allo-SCT) in Waldenström’s macroglobulinemia (WM).
The consensus was produced by international experts from the EBMT lymphoma working party (LWP), European Consortium for Waldenstrom’s Macroglobulinemia (ECWM) and International Waldenström’s Macroglobulinemia Foundation (IWMF) using the RAND-modified Delphi consensus method. Dr Kyriakou highlighted that the panel included European and North American lymphoma and transplant experts to take into account the difference of access to drugs in these countries.
The experts aimed to address a gap in the knowledge of the role of transplantation in WM however, the main challenge was the lack of evidence in such a rare disease. Eighteen statements were prepared and scored by the members and a consensus was successfully agreed on nine of the statements.
Dr Kyriakou stressed that, “it is important we individualize this treatment in this rare group of patients because we are not clear on the risk factors of this disease and also the clinical cause.” The consensus was also able to “identify areas of uncertainty for further research”.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox